SciClone Pharmaceuticals (SCLN) Stock Price, News & Analysis

Company Overview

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Key Stats

• Today's Range: $11.15 to $11.15
• 50-Day Range: N/A
• 52-Week Range: $8.55 to $11.43
• Volume: N/A
• Average Volume: 444,833 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCLN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of SciClone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SciClone Pharmaceuticals investors own include Bristol Myers Squibb (BMY), (ONCYF) (ONCYF), Gilead Sciences (GILD), Rite Aid (RAD), Skyworks Solutions (SWKS), Imunon (CLSN) and CTI BioPharma (CTIC).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SCLN
• CIK: 880771
• Web: www.sciclone.com
• Phone: +1-650-3583456
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A